Merck Patent Gmbh

Merck Patent Gesellschaft MIT Beschrankter Haftung

Jaume Adan

Francesc Mitjans

Jaume Piulats

Elisabet Rosell

Alfred Jonczyk

Guenter Hoelzemann

Simon Lawrence Goodman

Wilfried Rautenberg

Karl-August Ackermann

Helene Crassier

Diane Hahn

Elisabet Rosell-Vives

Kin-Ming Lo

Wolfgang Staehle

Mary M Bendig

Ana Carceller

Alicia Gomez

A Cathrine Kettleborough

Keith H Ansell

Detlef Gussow

Francesc Blasco

Marta Soler Riera

Claudia Cases

Gema Tarrason

The invention relates to engineered antibodies which specifically bind to integrin receptors, especially the alpha V integrin receptor subunit. The antibodies comprise the antigen binding sites (CDRs) of a known mouse anti-integrin antibody, as well as hybrid light chain variable sequences, mutated heavy chain variable sequences (Frs) and modified heavy chain constant sequences. The novel antibodies have improved immunogenic and expression properties and elicit excellent anti-angiogenic as well as anti-tumor activities in humans in monotherapy but also and above all in combination with other angiogenesis and tumor inhibiting agents.

Engineered anti-alpha V-integrin hybrid antibodies

Compounds of the formula (I), in which R, R, R, R, Het, X and X' have the meanings indicated in claim, are inhibitors of tyrosine kinases, in particular TIE-2, and Raf kinases and can be employed, inter alia, for the treatment of tumours. 

4-Amino-5-oxo-8-phenyl-5H-pyrido(2,3-D) pyrimidine derivatives as tyrosine kinase and raf kinase inhibitors for the treatment of tumours

The invention relates to compounds of formula (I) wherein R, R, R, R, R, R, R, R, R, X and X' have the designations cited in patent claim. Said compounds are inhibitors of tyrosine kinases, especially TIE-2, and Raf kinases, and can, inter alia, be used for the treatment of tumors. 

Pyridopyrimidinones

The invention relates to a novel monoclonal antibody, a hybridoma cell line producing said antibody, DNA sequences coding for said antibody, and amino acid sequences. The monoclonal antibody, a preferred embodiment of which is named 17E6, has the following properties:

Anti-.alpha.V-integrin monoclonal antibody

The present invention relates to anti-idiotypic antibodies which induce an immune response against tumors, bearing as antigen the epidermal growth factor receptor (EGFR). The antibodies of the invention may mimic said antigen. As preferred embodiment the antibodies of the invention derive from mAB 425 (ATCC HB 9629) or a humanized or chimeric derivative thereof.

Anti-idiotypic antibodies which induce an immune response against

Anti-EGFR single-chain Fvs and anti-EGFR antibodies

Growing community of inventors

Mataro, Spain

Jaume Adan